IDYA News

IDEAYA Biosciences, Inc. (IDYA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seekingalpha | 15 hours ago

Ideaya Biosciences: Darovasertib De-Risks A Self-Reinforcing Oncology Platform

IDEAYA Biosciences is transitioning into a commercial oncology platform, leveraging darovasertib's registrational success and a robust internal pipeline. Darovasertib's phase 2 trial showed a median PFS of 6.9 vs. 3.1 months, supporting NDA submission and U.S. commercialization prospects. With $1.24 billion in cash, IDYA can fund operations into 2030, enabling the advancement of multiple proprietary combination franchises.

Seekingalpha | 2 weeks ago

IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology Summit

IDEAYA Biosciences NASDAQ: IDYA executives highlighted recent clinical progress across the company's oncology pipeline during a fireside chat at TD Cowen's seventh annual Oncology Innovation Summit, with the discussion focused primarily on darovasertib combinations in uveal melanoma and several earlier-stage antibody-drug conjugate and synthetic lethality programs.

Marketbeat | 3 months ago

IDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA Filing

IDEAYA Biosciences NASDAQ: IDYA Chief Executive Yujiro Hata said the precision oncology company is preparing for a busy 2026, led by regulatory and clinical milestones for darovasertib in metastatic uveal melanoma and multiple data readouts across its pipeline.

Marketbeat | 3 months ago

IDEAYA Biosciences, Inc. (IDYA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seekingalpha | 4 months ago

IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates

IDEAYA Biosciences, Inc. (IDYA) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to a loss of $0.82 per share a year ago.

Zacks | 4 months ago

IDEAYA Biosciences, Inc. (IDYA) Discusses Topline Results from OptimUM-02 Trial Evaluating Darovasertib and Crizotinib in HLA-A2-Negative Metastatic Uveal Melanoma Transcript

Seekingalpha | 5 months ago

Ideaya Biosciences: Key Pivotal Data Imminent

Ideaya Biosciences is on the verge of a pivotal data readout for darovasertib, its lead uveal melanoma candidate. IDYA maintains a strong cash runway of 3–4 years, supporting a robust and expanding pipeline targeting multiple high-value oncology indications. Darovasertib has shown promising efficacy as both monotherapy and in combination, with phase 3 data expected imminently and potential for FDA approval.

Seekingalpha | 5 months ago

IDEAYA Biosciences, Inc. (IDYA) Discusses Pipeline Progress and Upcoming Data Readout in Uveal Melanoma and ADC Programs Transcript

Seekingalpha | 6 months ago

IDEAYA Biosciences, Inc. (IDYA) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

Ideaya Biosciences Inc. (IDYA)